Cargando…

Clozapine-induced parotitis: A case study

INTRODUCTION: Clozapine is the drug of choice for patients with an unsatisfactory response to classic antipsychotic treatment. Little is known about the involvement of clozapine in the development of parotid disease. OBJECTIVES: Identify the clinical characteristics of Clozapine-induced parotitis th...

Descripción completa

Detalles Bibliográficos
Autores principales: Kacem, M., Mami, H., Sellami, S., Moalla, M., Frej, S. Ben, Bouzid, R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cambridge University Press 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9475681/
http://dx.doi.org/10.1192/j.eurpsy.2021.1433
_version_ 1784789964885590016
author Kacem, M.
Mami, H.
Sellami, S.
Moalla, M.
Frej, S. Ben
Bouzid, R.
author_facet Kacem, M.
Mami, H.
Sellami, S.
Moalla, M.
Frej, S. Ben
Bouzid, R.
author_sort Kacem, M.
collection PubMed
description INTRODUCTION: Clozapine is the drug of choice for patients with an unsatisfactory response to classic antipsychotic treatment. Little is known about the involvement of clozapine in the development of parotid disease. OBJECTIVES: Identify the clinical characteristics of Clozapine-induced parotitis through a case and literature review. METHODS: We report the case of a patient with a refractory schizoaffective disorder, bipolar type and who developed recurrent parotitis while taking clozapine. We conducted a literature review based on a PubMed search of articles published on this subject with the following keywords: ‘parotitis clozapine’. RESULTS: Miss W., 34 years old, suffers from a severe schizoaffective disorder that has been diagnosed for several years. She has received various psychotropic medications. She suffered from frequent relapses that required recurrent hospital admissions. One year ago, a diagnosis of treatment-resistant schizoaffective disorder was made. The decision to introduce clozapine, associated with mood stabilizer treatment, was made on the basis of her treatment refractory symptoms. She experienced considerable sialorrhea after beginning clozapine treatment. Miss W. developed bilateral recurrent swelling over both temporal-mandibular areas after 6 months of treatment. It often appears after eating and lasts from 4 to 6 hours. There was no change in white blood cell count and she was afebrile. An otolaryngologist was consulted and a diagnosis of clozapine-induced parotitis was suggested. A spasmolytic and an anticholinergic treatment were prescribed and clozapine was continued. CONCLUSIONS: This iatrogenic effect of clozapine must be recognized by clinicians in order to be better prevented.
format Online
Article
Text
id pubmed-9475681
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Cambridge University Press
record_format MEDLINE/PubMed
spelling pubmed-94756812022-09-29 Clozapine-induced parotitis: A case study Kacem, M. Mami, H. Sellami, S. Moalla, M. Frej, S. Ben Bouzid, R. Eur Psychiatry Abstract INTRODUCTION: Clozapine is the drug of choice for patients with an unsatisfactory response to classic antipsychotic treatment. Little is known about the involvement of clozapine in the development of parotid disease. OBJECTIVES: Identify the clinical characteristics of Clozapine-induced parotitis through a case and literature review. METHODS: We report the case of a patient with a refractory schizoaffective disorder, bipolar type and who developed recurrent parotitis while taking clozapine. We conducted a literature review based on a PubMed search of articles published on this subject with the following keywords: ‘parotitis clozapine’. RESULTS: Miss W., 34 years old, suffers from a severe schizoaffective disorder that has been diagnosed for several years. She has received various psychotropic medications. She suffered from frequent relapses that required recurrent hospital admissions. One year ago, a diagnosis of treatment-resistant schizoaffective disorder was made. The decision to introduce clozapine, associated with mood stabilizer treatment, was made on the basis of her treatment refractory symptoms. She experienced considerable sialorrhea after beginning clozapine treatment. Miss W. developed bilateral recurrent swelling over both temporal-mandibular areas after 6 months of treatment. It often appears after eating and lasts from 4 to 6 hours. There was no change in white blood cell count and she was afebrile. An otolaryngologist was consulted and a diagnosis of clozapine-induced parotitis was suggested. A spasmolytic and an anticholinergic treatment were prescribed and clozapine was continued. CONCLUSIONS: This iatrogenic effect of clozapine must be recognized by clinicians in order to be better prevented. Cambridge University Press 2021-08-13 /pmc/articles/PMC9475681/ http://dx.doi.org/10.1192/j.eurpsy.2021.1433 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Abstract
Kacem, M.
Mami, H.
Sellami, S.
Moalla, M.
Frej, S. Ben
Bouzid, R.
Clozapine-induced parotitis: A case study
title Clozapine-induced parotitis: A case study
title_full Clozapine-induced parotitis: A case study
title_fullStr Clozapine-induced parotitis: A case study
title_full_unstemmed Clozapine-induced parotitis: A case study
title_short Clozapine-induced parotitis: A case study
title_sort clozapine-induced parotitis: a case study
topic Abstract
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9475681/
http://dx.doi.org/10.1192/j.eurpsy.2021.1433
work_keys_str_mv AT kacemm clozapineinducedparotitisacasestudy
AT mamih clozapineinducedparotitisacasestudy
AT sellamis clozapineinducedparotitisacasestudy
AT moallam clozapineinducedparotitisacasestudy
AT frejsben clozapineinducedparotitisacasestudy
AT bouzidr clozapineinducedparotitisacasestudy